RxDoctor Payments Data

Donna Brazell

Family · Idalou, TXNPI 1346354818

Payments from drug & device makers

$1,754in general payments, 2019–2025

Across 36 payments — averaging $48.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$167
  • Arbor Pharmaceuticals, Inc.$120
  • Amgen$100
  • Lilly USA, LLC$68
  • Novo Nordisk$49
  • plus $70 from 3 others

What the payments were for

  • Speaking & faculty fees$97556%
  • Food & beverage$77944%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,754 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$57,869
Medicare patients
166
Services billed
2,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$80,261
JardianceEmpagliflozin73$65,278
OzempicSemaglutide40$52,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$29,856
EliquisApixaban25$26,836
TrulicityDulaglutide22$21,490
JanuviaSitagliptin Phosphate19$16,838
FarxigaDapagliflozin Propanediol11$14,728
MyrbetriqMirabegron24$13,424
Tresiba Flextouch U-100Insulin Degludec12$6,246
TrintellixVortioxetine Hydrobromide12$5,508
SymbicortBudesonide/Formoterol Fumarate14$5,303
PremarinEstrogens, Conjugated12$5,175
Levothyroxine Sodium278$3,113
Icosapent Ethyl14$3,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$68$101,75175 claims
Novo NordiskOzempic$49$52,42140 claims
GSKTrelegy Ellipta$167$29,85640 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$42$5,50812 claims
AbbVieSynthroid$1,180$1,37828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in Idalou

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →